Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer

JAMA - Journal of the American Medical Association

Volumn 317, Issue 11, 2017, Pages 1141-1150

  Chen, Ronald C ^a,b   Basak, Ramsankar ^a   Meyer, Anne Marie ^b,c   Kuo, Tzy Mey ^b   Carpenter, William R ^b   Agans, Robert P ^b   Broughman, James R ^a   Reeve, Bryce B ^b,c   Nielsen, Matthew E ^a,b,c   Usinger, Deborah S ^b   Spearman, Kiayni C ^b   Walden, Sarah ^b   Kaleel, Dianne ^b   Anderson, Mary ^d   Stürmer, Til ^b,c   Godley, Paul A ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c IL   (United States)

^d Prostate Cancer Coalition of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER LOCALIZATION; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENTEROPATHY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; MEN'S HEALTH; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; URINARY IRRITATION; URINARY TRACT DISEASE; URINARY TRACT OBSTRUCTION; URINE INCONTINENCE; ADVERSE EFFECTS; BLOOD; COITUS; COMPARATIVE STUDY; ERECTILE DYSFUNCTION; INTENSITY MODULATED RADIATION THERAPY; INTESTINAL DISEASES; MIDDLE AGED; NORTH CAROLINA; PATHOLOGY; PATHOPHYSIOLOGY; PROPENSITY SCORE; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; ROBOTIC SURGICAL PROCEDURE; STATISTICS AND NUMERICAL DATA; TIME FACTOR; URINARY INCONTINENCE; URINARY RETENTION; URINATION DISORDERS; WATCHFUL WAITING;

PROSTATE SPECIFIC ANTIGEN;

AGED; BRACHYTHERAPY; COITUS; ERECTILE DYSFUNCTION; HUMANS; INTESTINAL DISEASES; MALE; MIDDLE AGED; NORTH CAROLINA; PROPENSITY SCORE; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY, INTENSITY-MODULATED; ROBOTIC SURGICAL PROCEDURES; TIME FACTORS; URINARY INCONTINENCE; URINARY RETENTION; URINATION DISORDERS; WATCHFUL WAITING;

EID: 85016109444     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.1652     Document Type: Article

References (29)

1. Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research.Washington, DC: National Academies Press; 2009.
2. Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307(15):1611-1620.
3. LowranceWT, Eastham JA, Savage C, et al. Contemporary open and robotic radical prostatectomy practice patterns among urologists in the United States. J Urol. 2012;187(6):2087-2092.
4. Donovan JL, Hamdy FC, Lane JA, et al; ProtecT Study Group. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425-1437.
5. Chen RC, Rumble RB, Loblaw DA, et al. Active surveillance for the management of localized prostate cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016; 34(18):2182-2190.
6. Clark JA, Talcott JA. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care. 2001;39(10):1118-1130.
7. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358 (12):1250-1261.
8. Martin NE, Massey L, Stowell C, et al. Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol. 2015; 67(3):460-467.
9. Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: How localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol. 2009;27(24):3916-3922.
10. Chen RC, Chang P, Vetter RJ, et al. Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. J Natl Cancer Inst. 2014;106(7):dju132.
11. Mushlin AI, Ghomrawi H. Health care reform and the need for comparative-effectiveness research. N Engl J Med. 2010;362(3):e6.
12. Talcott JA, Clark JA, Manola J, Mitchell SP. Bringing prostate cancer quality of life research back to the bedside: Translating numbers into a format that patients can understand. J Urol. 2006; 176(4 pt 1):1558-1563; discussion 1563-1564.
13. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res. 2007;16(3): 219-242.
14. Stürmer T, Wyss R, Glynn RJ, BrookhartMA. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med. 2014;275(6):570-580.
15. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28): 3661-3679.
16. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30(4):377-399.
17. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care. 2003;41(5):582-592.
18. Norman GR, Sloan JA, Wyrwich KW. The truly remarkable universality of half a standard deviation: Confirmation through another look. Expert Rev Pharmacoecon Outcomes Res. 2004;4(5):581-585.
19. Wright JG. Interpreting health-related quality of life scores: The simple rule of 7may not be so simple. Med Care. 2003;41(5):597-598.
20. Chen RC, Carpenter WR, Kim M, et al. Design of the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study (NC ProCESS). J Comp Eff Res. 2015;4(1):3-9.
21. US Preventive Services Task Force. Final research plan for prostate cancer: Screening. http://www.uspreventiveservicestaskforce.org /Page/Document/final-research-plan/prostate -cancer-screening1. Accessed September 1, 2016.
22. Oberlin DT, Flum AS, Lai JD, Meeks JJ. The effect of minimally invasive prostatectomy on practice patterns of American urologists. Urol Oncol. 2016;34(6):255.e1-255.e5.
23. Safdieh J, Wong A, Weiner JP, Schwartz D, Schreiber D. Utilization of prostate brachytherapy for low risk prostate cancer: Is the decline overstated?. J Contemp Brachytherapy. 2016;8(4): 289-293.
24. Wilt TJ. The Prostate Cancer Intervention vs Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): Design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer. J Natl Cancer Inst Monogr. 2012;2012(45):184-190.
25. Steineck G, Helgesen F, Adolfsson J, et al; Scandinavian Prostatic Cancer Group Study Number 4. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347(11):790-796.
26. Chang P, Regan MM, Ferrer M, et al; PROST-QA Consortium. Relief of urinary symptom burden after primary prostate cancer treatment. J Urol. 2017;197 (2):376-384.
27. Yaxley JW, Coughlin GD, Chambers SK, et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: Early outcomes from a randomised controlled phase 3 study. Lancet. 2016;388(10049):1057-1066.
28. Potosky AL, Harlan LC, Stanford JL, et al. Prostate cancer practice patterns and quality of life: The Prostate Cancer Outcomes Study. J Natl Cancer Inst. 1999;91(20):1719-1724.
29. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271-289.